Sutro Biopharma, Inc. (STRO) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-23
Business type: Asset play
How it makes money
It earns revenue by licensing proprietary drug-discovery platforms and clinical assets to pharmaceutical companies.
The company monetizes its XpressCF and XpressCF+ platforms by entering into multitarget, product-focused collaborations with larger pharmaceutical and biotechnology firms. Profitability is driven by its ability to successfully out-license its preclinical or clinical-stage drug candidates to these partners for development and potential future commercialization, as it currently lacks any products approved for sale.
What growth costs
It incurs significant research and development expenses and must raise substantial capital to fund clinical trials and platform advancement.
Growth requires constant reinvestment into preclinical studies, clinical trials, and general infrastructure to support its evolution into a clinical-stage entity. Because the company generates no product revenue, these costs are funded through capital raises and potential collaboration payments.
What could damage it
A failure in clinical trials or a inability to raise funding would permanently end its ability to advance its pipeline.
Since the business model relies entirely on the successful validation and out-licensing of its drug candidates, negative clinical trial results or an inability to secure additional capital would halt operations, as the company has no other source of commercial revenue to sustain itself.
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as an oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF; and site-specific conjugation platform, XpressCF+. Its lead product candidate includes STRO-004, a tissue factor (TF) targeting ADC for the treatment of TF-expressing solid tumors, including non-small cell lung cancer, head and neck squamous cell carcinoma, cervical cancer, colorectal cancer, pancreatic ductal adenocarcinoma, endometrial cancer, and bladder cancer. The company also develops VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease in adults and adults and infants; and STRO-003, an ADC directed against an anti-receptor tyrosine kinase-like orphan receptor 1 (ROR1) for the treatment of solid tumors, such as triple negative breast cancer, non-small cell lung cancer, and ovarian cancer, as well as hematological cancers. Sutro Biopharma, Inc. has collaboration and license agreements with Vaxcyte to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases; Tasly Biopharmaceuticals Co., Ltd. to develop and commercialize STRO-002 in Greater China; Ipsen to develop and commercialize STRO-003, an ADC targeting ROR1; and Astellas Pharma Inc. to develop immunostimulatory ADC. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.